Biotech Takes Innovative Approach To Raising Capital For Its Promising Anti-Cancer Drug

Dr. Vuong Trieu, CEO & Chairman of Oncotelic Therapeutics, Inc. was recently a guest on Benzinga’s All-Access.

Oncotelic is a biotechnology company focused on developing RNA therapeutics for hard-to-treat cancers. The company has extensive experience in the field and its lead candidate OT-101 has shown very positive results in trials. 

Money in biotech is hard to come by these days and Oncotelic has taken an innovative approach to fundraising for the commercialization of OT-101. It has created a joint venture with GMP Biotechnology, Sapu Bioscience, which it plans to take public.

Learn more here:

Featured photo by CDC on Unsplash..

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechInterviewGeneralBenzinga All AccessOncotelic Therapeutics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!